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Abstract
Background: Mosquito-borne viruses are imposing an ever increasing health burden worldwide. In addition to the
recent Zika and chikungunya virus epidemics, dengue viruses have become the fastest growing problem with a 40-
fold increase in the number of reported cases over the past five decades. Current mosquito control techniques
involving larval source reduction, larviciding, and space spray of adulticides are costly, laborious, and of debatable
efficacy. There remains an urgent need for the development of intervention methods that can be reasonably
implemented in the context of modern day urbanisation. Auto-dissemination (AD) of insecticide by adult
mosquitoes offers a potentially practical and useful tool in an integrated vector control programme. Recently, an
immediately employable AD device, the In2Care® mosquito trap, has been commercialised and shows promise as
an effective tool. However, there remains a lack of demonstration of epidemiological efficacy.
Methods/design: This trial aims to assess the extent to which implementation of In2Care® mosquito traps can reduce
vector Aedes (Stegomyia) spp. adult mosquito densities and dengue virus transmission as measured by sequential sero-
conversion rates in children 6–16 years of age in a dengue endemic location: Lipa City, Philippines. To achieve this, we
will carry out a parallel, two-armed cluster randomised trial evaluating AD efficacy for reducing the incidence of
dengue over a 2-year period with 4 consecutive months of vector control during peak dengue transmission each year.
Discussion: For decades, it has been commonly accepted that an integrated approach to mosquito control is
required. The World Health Organization (WHO) Global Strategic Framework for Integrated Vector Management
recommends a range of interventions, in combination, to increase control impact to reduce transmission. This efficacy
trial of the first commercial product using the AD approach will be informative in assessing the general utility of AD in
reducing not only adult vector densities but, more importantly, reducing the incidence of dengue. The AD technique
may complement source reduction and larviciding campaigns by more efficiently targeting the most productive
containers and those beyond human reach. If successful, this mosquito control strategy could prove an invaluable tool
in the fight against urban mosquito vectors and a reduction in the burden of associated disease.
Trial registration: ISRCTN44272773. Registered on 31 January 2019.
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Background
Mosquito-borne viruses of public health importance are
imposing an ever increasing burden worldwide. In
addition to the recent notable epidemics of West Nile,
Zika, and chikungunya viruses, the dengue viruses in
particular have become the fastest growing problem with
a 40-fold increase globally in the number of reported
cases over the past five decades affecting over 100 coun-
tries [1]. Currently, an estimated 400 million dengue
virus (DENV) infections occur annually, of which only a
quarter or less become symptomatic [2]. Of these, a
small percentage manifest into more severe forms of the
disease: dengue haemorrhagic fever and/or dengue shock
syndrome and potentially death. The primary mosquito
species responsible for DENV transmission is Aedes
aegypti (L.), a species that has adapted to an urban habi-
tat, proliferating in artificial water containers arising pri-
marily from solid waste and frequent long-term water
storage. Rates of urbanisation are increasing dramatically
globally, particularly in regions of high socio-economic
vulnerability, exacerbating an already over-stretched in-
frastructure and low public service capacity. The in-
creasing frequency and amplitude of dengue epidemics
bears testament to the scale of the threat and the urgent
need to address these diseases in the context of a rapidly
changing urban landscape [3].
Despite progress in the development of vaccines for
preventing chikungunya, dengue, and Zika infections
[4–6], no current candidates appear likely to have gen-
eral application in endemic areas. Therefore, it is gener-
ally agreed that an integrated approach to control,
including a significant role for vector abatement, will be
required [7, 8]. For over 100 years, the most common
dengue control strategy has been source (larval habitat)
reduction and focal insecticide treatment of mosquito
larval habitats (so-called ‘breeding sites’). This approach
helped to eliminate Ae. aegypti from 22 countries in the
Americas during control campaigns in the 1950s and
1960s [9]. However, these activities required enormous
human resources and costs to support, making them un-
sustainable in the long term. Today, the scale of con-
tinuing urban expansion abnegates such an approach.
Current mosquito control techniques based on larval
habitat source reduction, larviciding, and space spray are
costly, laborious, and of debatable efficacy depending on
the circumstances [10, 11]; therefore, there remains an
urgent need for the development of intervention
methods that could be reasonably implemented in the
context of modern day urban environments and with
some measure of possible sustainability. One of the
major challenges in large, condensed urban settings is
achieving sufficient coverage of aquatic habitats
preferred by Ae. aegypti [12]. Identifying and treating all
possible breeding sites manually is not a realistic
solution even with considerable organised community
support and resources.
One potential solution, originally proposed by Itoh et al.
[13], is to exploit the ‘skip-oviposition’ behaviour of adult
female Ae. aegypti to disseminate insecticide to natural
larval habitats [14], in other words female mosquitoes ex-
posed to a surface contaminated with insecticide subse-
quently spread it to other aquatic sites during oviposition
[12, 15], a mechanism called auto-dissemination (AD). In-
sofar as the mosquitoes cannot “carry” substantial
amounts of the particulate chemical matter on their tarsi
and the insecticide must work in even large volumes of
water, the insecticide must be potent at very minute
(nanogram) concentrations. Furthermore, given the rela-
tively indiscriminate dissemination of the insecticide, it
must also be non-toxic to vertebrates and have a relatively
narrow range of action against other aquatic invertebrates.
Pyriproxyfen (PPF) ticks all the boxes [16]. This World
Health Organization (WHO) approved pupacide can be
safely used in drinking water and is recommended as part
of conventional programmes against Ae. aegypti [17, 18].
It is a synthetic analogue of juvenile hormone which, at
very low concentrations, prevents larval and pupal devel-
opment as well as female fertility and male spermiogenesis
[19, 20]. Currently it is applied as either granular or liquid
formulations directly to water containers and drains in
South America and South East Asia with documented
success in reducing immature and adult mosquito num-
bers and has been associated with a reduction in dengue
incidence [21, 22]. The potential of PPF application via
AD has been demonstrated in a variety of small-scale trials
in Peru and Italy [12, 15] and on a larger scale in the Ama-
zon [23]. However, whilst entomological efficacy of PPF
has been demonstrated when applied through AD, ground
space spray, or container treatment, evidence of actual
epidemiological impact (infection reduction) is generally
inconclusive [24, 25].
Recently, a commercialised AD device, the In2Care®
mosquito trap (In2Care® BV, Wageningen, Netherlands)
[26], has been validated in field studies in the Grand
Cayman, yielding pupal mortality rates of ~ 60% (unpub-
lished data). The In2Care® trap attracts ovipositing Ae.
aegypti females, which are then contaminated with a
combination of PPF and an entomopathogenic fungus,
Beauvaria bassiana, a United States Environmental Pro-
tection Agency approved agent that has been used in
biological control of many agricultural pests for decades
[27]. The lethal and pre-lethal (e.g. reduced feeding pro-
pensity) effects of the fungus have been described in
Anopheles and Aedes species in which it takes several
days to kill the adult insect, thereby allowing the mos-
quito to disseminate the PPF component [28, 29]. The
fungal infection also interferes with DENV replication
within the mosquito, thus having a profound effect on
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mosquito vectorial capacity (i.e. transmission efficacy)
beyond that of shortening the adult mosquito lifespan
[30]. The In2Care® mosquito trap thus uses an AD ap-
proach to disseminate a pupacide combined with a dir-
ect action, slow-acting entomopathogenic adulticide.
This study proposes to evaluate the epidemiological
and entomological efficacy of the In2Care® trap in a
dengue-endemic urban location in the Philippines.
Methods/design
Objectives
The primary objective of the trial is to assess the extent
to which implementation of In2Care® mosquito traps
can reduce Ae. aegypti adult mosquito densities and
DENV sero-conversion rates (i.e. transmission) in chil-
dren 6–16 years of age in a site of endemic dengue risk
in the Philippines.
Study type
The study is a parallel, two-armed cluster randomised
trial (PCRT) evaluating the efficacy of the In2Care® mos-
quito trap for reducing incidence of dengue infection
over a 2-year period using 4 consecutive months of
treatment each year.
Previous studies have estimated that, to account for
the unpredictable spatio-temporal heterogeneity in den-
gue transmission, PCRTs are the most effective study de-
sign and that a larger number of clusters with fewer
children per cluster provide the optimal strategy—in ef-
fect, a bet-hedging approach for a statistically sufficient
coverage of an area [31]. In order to attempt to control
for the spatial heterogeneity in dengue occurrence, 46
areas (hereafter referred to as “clusters”), each of ap-
proximately 200m in radius, will be pre-selected.
Twenty-three clusters will be assigned to the treatment
arm with In2Care® traps and 23 to the control arm with-
out traps. Cluster sites assigned to treatment versus con-
trol arms will be matched according to retrospective
incidence of reported dengue clinical cases over the pre-
vious 5 years and human population density (See Stratifi-
cation scheme below). Because of ‘edge effects’, where
individuals near the periphery of the treatment area will
be potentially subject to contact with mosquitoes com-
ing from neighbouring non-treated areas, we will imple-
ment the “fried egg” design [32] whereby we will assess
sero-conversion only in children resident at least 50 m
from the treatment zone edge. Thus, whilst we will im-
plement In2Care® traps throughout a 200 m radius circle,
we will only consider sero-conversion in children within
a 150 m radius (Fig. 1). One hundred schoolchildren
(between 6 and 16 years of age) will be recruited for re-
peated sero-conversion observation within the inner cir-
cle of each of the 46 clusters (See Sample size
calculations below). As the population density in clusters
will vary, it is possible that there will not be sufficient
children within a prescribed area. In this case, we will in-
crease the circle radius to reach the required sample
number.
Adult Aedes mosquito densities will be monitored
in treatment and control sites by the use of Gravid
Aedes Traps (GATs; Biogents AG, Regensburg,
Germany) (Additional file 1). GATs are more efficient
in capturing gravid Ae. aegypti than sticky ovitraps
and are practical, low cost, and easily transportable
devices, essential attributes in large-scale monitoring
programmes [33].
Stratification scheme
Clusters will be stratified according to historical den-
gue incidence and population density. In the
Philippines, a barangay is the smallest administrative
division in the Philippines (urban or rural), but which
can be subdivided into puroks (zones) consisting of
20 to 50 households depending on the location and
density of the households in an area. The previous 5
years of dengue incidence data at the purok adminis-
trative unit level will be acquired from the Philippines
Integrated Disease Surveillance and Response (PIDSR)
system to identify relative defined ‘hotspots’ and ‘cold-
spots’ of dengue activity during that period. This in-
formation will be entered into the Disease Data
Management System (DDMS+) (see Data management
below) along with information on geography, popula-
tion density, and infrastructure at the barangay level.
This will generate maps with which to choose clusters
Fig. 1 Intervention and sampling strategy. The yellow region
includes recruited children for the sero-conversion study and the
outer peripheral region is the buffer zone also treated with AD
devices (blue jar icons) but without sero-conversion saliva sampling
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for the intervention study and assign clusters to ei-
ther treatment or control groups according to broad
similarities.
Sample size calculations
The sample size is calculated using the following
standard formula when considering proportions (inci-
dence rate):
n ¼ 2 Zaþ Z1 βð Þ2 p 1 pð Þ= p0 p1ð Þ2
Where n is the required sample size per treatment
arm (control or treatment), Zα and Z1–β are constants
set by convention according to the accepted α error and
whether a one-sided or two-sided effect, p0 is the pro-
portion infected in control areas, and p1 the proportion
infected in treatment areas (p = (p0+p1)/2).
Assuming a p < 0.05 as acceptable and a study with
90% power, the following constant values are: Zα = 1.96
(two-tailed); Z1–β = 1.2816.
The final sample size will depend on the dengue trans-
mission rate in the study areas as estimated from the
historical mean rate. Recent sero-conversion studies in
Cebu City, Philippines, have observed a symptomatic in-
cidence rate of 1.6 per 100 person-years (1.6%) with 7%
subclinical infections in the general population, increas-
ing to 7% symptomatic cases and 17% subclinical infec-
tions in children < 15 years old [34]. Historical annual
incidence rates were estimated at between 11 and 22%
[35]. Reported incidence rates in our study area (under
administrative Region IV-A) are consistently amongst
the highest in the country. To be conservative, however,
we estimate an infection incidence of 3% (to include
symptomatic and subclinical infections). For an efficacy
of treatment of 50% (i.e. reduction in dengue), with 90%
power, a minimum of 2054 children (aged 6–16 years
old) will need to be recruited in treatment sites with an
equivalent number in matched control sites and followed
for 2 years. We factor in a drop-out of 250 children (~
12.2%) per treatment and control arm (500 total) over
the 2-year period. Thus, the total number of children to
be recruited is 4600, distributed over 46 clusters of 100
children each.
Setting (Fig. 2)
Dengue is endemic throughout much of the
Philippines, and between 2008 and 2012 the country’s
Department of Health (DoH) reported an annual
average of 117,065 diagnosed (symptomatic) dengue
cases, although the number is likely to be far higher
because of significant under-reporting [36]. Region
IV-A (Calabarzon) has consistently had a high burden
of dengue and was one of three regions where the
dengue vaccine (Dengvaxia®, Sanofi Pasteur) was
implemented. According to an official DoH report, in
2018 the Calabarzon region was the area most af-
fected by dengue, accounting for 19% of all national
cases, while also showing an increase in case load of
40% in comparison with the same time period the
previous year. Lipa City is a large city in the Calabar-
zon region and is located approximately 78 km south
of Manila at an altitude of 312 m, covering an area of
209.40 km2 with a population of 332,386 people in
2015. The city is subdivided into 72 barangays of
varying human density (at an average of ~ 1800/km2).
The average annual temperature is 28 °C (82 °F) and
the peak dengue transmission season typically occurs
during increased rains from June to December.
Outcomes
The principle evaluation criterion is the epidemio-
logical efficacy read out: dengue infection
sero-conversion. Sero-conversion to dengue virus ex-
posure will be measured by an enzyme-linked im-
munosorbent assay (ELISA) for immunoglobulin (Ig)G
titres using repeated saliva samples taken sequentially
during three cross-sectional studies at months 0, 3
(end of month 2), and 5 (end of month 4) during the
intervention (In2Care® trap placement) period each
year in both treatment and control sites. These time
points are designated Pre-, Post1, and Post2 within
each year.
The secondary evaluation criterion is the entomo-
logical read out. To measure the impact of the
In2Care® traps on the adult mosquito population
densities, 20 GATs will be placed in each of 10 ran-
domly selected treatment and 10 control sites
matched with intervention sites for historical dengue
incidence. Aedes spp. (both Ae. aegypti and Ae. albo-
pictus) adults will be counted and identified in the
GATs once each week beginning 2 weeks before inter-
vention, throughout the intervention period, and 2
weeks post-intervention. Traps will be placed both in-
side and outside 10 randomly selected houses within
each site. Traps placed outside will be positioned
against the wall of the house in an area with shelter
from direct sunlight. Traps placed inside the house
will be positioned in a suitably unobstructed area but
where there is air movement.
Study subject eligibility criteria
Inclusion criteria include: male and female individuals
6–16 years old; a parent/guardian giving informed con-
sent for the child’s participation in the study; and, for
children > 7 years old, required assent for his/her partici-
pation in the study and written assent from children 12–
16 years old.
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The exclusion criterion is a child with known con-
comitant pathology(ies) at the time of the consent as in-
dicated by the parent/guardian
Recruitment
In each barangay pre-selected to participate in the study,
Research Institute for Tropical Medicine (RITM) team
members will hold general information meetings on the
project with the population in the presence of the com-
munity (barangay) health workers (BHWs) and local
public health officials. Because the volunteers to be re-
cruited are of school age, additional information meet-
ings will be held in the local schools. Once clusters are
identified and randomly assigned with appropriate strati-
fication, the study team will perform household visits
with the Lipa City public health staff and respective area
BHWs. The visit will explain the study and study proto-
col in detail and request individual informed consent/
assent for periodic saliva sampling and mosquito trap
placement by each household head (In2Care® and/or
GATs) in and around participant’s houses (See Ethics ap-
proval and consent to participate below).
Following signed consent, a short questionnaire per-
taining to the participant will be completed and the
individual assigned a unique identifier barcode. The
questionnaire will be completed on paper including
details on: name, address, age, sex, whether having re-
ceived the Dengvaxia® vaccine (and if yes, how many
injections) or not, and the attending school and year
(grade). The individual’s barcode will be placed next
to their name on the consent form and kept in a sep-
arate file. Subsequent samples will also be labelled
with a unique barcode and linked back to the individ-
ual’s barcode in the questionnaire.
Data confidentiality
During field investigations, a file with a name and ad-
dress and corresponding barcode assigned to the subject
identity will be used. This file will only be accessible to
the field investigations team members who have direct
contact with the participants. To ensure confidentiality,
the file will be kept in an access-limited and secured
(locked) cabinet. Upon completion of the field work, the
address of the individual will be removed from the data-
base, with irreversible anonymisation. Fieldwork will in-
volve initial paper files that will then be input into an
electronic file which will be accessible only to the field
investigation team.
Study compliance will strictly adhere to the Republic
Act No. 10173 (Philippines Data Privacy Act) stipulating
full protection of an individual’s personal information by
coding and secure data storage, with no dissemination of
this information outside the study context. Participants
can request their personal information to be removed
and destroyed at any time during the study, which will
also result in the withdrawal of the participant from the
study.
Intervention (Fig. 3)
Throughout the study period, local health authorities
will continue with their routine government approved
dengue control strategies. Our intervention study will
in no way replace the current mosquito control
methods in use.
Fig. 2 Maps of the study site. a The Philippines; b Lipa City barangays
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For the intervention study, 46 clusters will be se-
lected each covering an area with at least 100 chil-
dren. Mean child (age 6–16 years) densities in urban
sites are 18/ha (/0.01 km2). Thus, an average sam-
pling radius of 140 m (6.15 ha) would generate 100
children (excluding 10% outright refusal) to be re-
cruited with an additional 50 m radius buffer zone for
treatment but without saliva sampling. The area to be
treated would thus be 113,000 m2 per cluster and
would require 113 AD devices at a density of 1 trap/
1000 m2 per treated cluster (23 study clusters to be
treated). Before geolocalisation of historical dengue
cases, however, we cannot predict which sites will be
selected, nor their actual human densities, and thus
the initial calculations are based on mean densities.
Treatment of areas with In2Care® devices will be
carried out for 4 months each year and the active
ingredient sachet (combination PPF + fungus) replaced
every 6 weeks. Each In2Care® trap will be assembled
(Additional file 2) and filled with 3.5–4.5 l of clean tap
water. One pesticide-treated netting removed from the
active ingredient sachet will then be placed on the
floater and the remaining contents of the sachet tipped
into the water. Each (10 × 18 cm) sealed aluminium re-
fill sachet contains: 0.5 g In2Mix (containing 10%
Beauveria bassiana strain GHA (Chemical Abstracts
Service (CAS) No. 63428–82-0), 74.03% pyriproxyfen
(CAS No. 95737–68-1), 0.97% pyriproxyfen impurity,
and 15% insert silicon dioxide); one 5 × 49 cm gauze
strip; and two yeast food supplement tablets of com-
mon brewer’s yeast (Saccharomyces cerevisiae). The
tablets are added to the trap tap water to emit organic
odours attractive for egg-laying mosquitoes.
In2Care® traps will be placed in open areas outside of
the house. GATs will be placed inside and outside
houses at designated locations. GATs will be assembled
as per the manufacturer’s instructions and filled with
water to which a handful of dry grass/hay will be added.
A sticky strip is placed inside the GAT and used to cap-
ture entering mosquitoes (Additional file 3). The general
state of the traps (In2Care® and GATs) will be assessed
during the weekly GAT counts and water replenished
where necessary. Likewise, the dried grass and water in
the GATs will be replaced during the weekly survey.
After 6 weeks, the netting, active ingredient, and yeast
tablets from the sachet of the In2Care® mosquito trap
will be replaced with a new sachet and new water. At
the end of the 4-month treatment period, all mosquito
traps will be removed, properly cleaned, and stored until
the following year.
Fig. 3 Time schedule of enrolment, interventions, and post-allocation data collections (based on SPIRIT 2013 figure [37]). HH Household
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Saliva sampling and biological analyses
A saliva sample will be taken by spitting into a sterile
urine collection container, kept on ice, and transported
to RITM for further processing. A 1-mL aliquot will be
placed in a labelled Eppendorf® tube for storage at −20 °
C. Sampling will occur just prior to, during (after 2
months of trap deployment), and at the end of the
4-month intervention period for 2 successive years.
Sero-conversion testing will be performed using an
in-house ELISA developed by Institut Pasteur [38] in du-
plicate on “paired” pre-/concurrent/post-samples from
the same individual for each season. Although IgM titres
will rise during a secondary DENV infection, a signifi-
cant increase in IgM titres only systematically occurs in
primary dengue infections and is relatively short lived;
therefore, changes in IgG titres will be measured [38].
Exposure to dengue virus will produce an increase in
IgG titre compared with the baseline titre in an individ-
ual, irrespective of whether they have been vaccinated or
not or having been previously exposed to any DENV
serotype (See Statistical analyses below). The technicians
performing the ELISAs will have no prior knowledge
whether the samples come from a treatment or control
site. Upon study completion, analyses, and publication,
all saliva samples will be destroyed and coding files
erased.
Specific data collection
For each participating child, information on their name,
age, sex, address, barangay, cluster number, dengue vac-
cination status, school, class, and subsequent dengue
ELISA titres will be recorded using a paper case report
form that will be subsequently input into a study elec-
tronic database. Unique bar codes will be used as
identifiers.
Data will be entered directly into DDMS (See Data
management below) with 10% cross-checking.
Data will remain secured at the Entomology unit in
RITM, Alabang, The Philippines. Statistical analysis will
be performed in RITM.
After the final saliva sample has been taken and the
data cross-checked for errors, the file linking the individ-
ual’s name and code will be destroyed.
Benefits to the individual and the community
Study volunteers and their parents will be informed on
their specific sero-conversion ELISA findings during an
annual feedback meeting. Whilst not providing a defini-
tive diagnostic for infection, at a minimum this will in-
form individuals whether they are sero-positive for
dengue and whether they have had a primary or
post-primary infection. Because there is an increased risk
of severe disease in post-primary infections, this infor-
mation could enable individuals to enhance their efforts
for personal protection from mosquito bites. A major
benefit of the study is directed to the entire community,
and potentially the entire country and beyond, if there is
evidence that the use of In2Care® mosquito traps can de-
crease the risk of dengue transmission.
Data management
Emerging innovative information technologies, such
as data management system software packages, can
assist disease control programmes to better manage
and analyse data, and thus make it easier to carry out
routine surveillance, monitor interventions, and evalu-
ate control programme performance. This will lead to
better informed decision making and actions on the
part of health authorities. The Liverpool School of
Tropical Medicine have developed a multi-disease
data management system (DDMS+) platform that fa-
cilitates the real-time monitoring and evaluation of
interventions that are essential for understanding the
progress, success, and challenges facing disease con-
trol operations [39]. DDMS+ is an open source data
management software program that works as a modu-
lar, integrated system. Currently, DDMS+ has been
successfully trialled for other vector-borne diseases in
eight countries for malaria and one for leishmaniasis.
The DDMS+ will be implemented for the dengue
study and bring this state-of-the-art technology to the
Philippines Department of Health through training
exercises and workshops.
Statistical analyses
Classification of dengue incidence as ‘hot’, ‘intermediate’,
and ‘cold’ spots
Dengue incidence for the previous 5 years will be ac-
quired at the purok level, and the midpoint of the purok
used as the geographical coordinate representing the
purok. Population density at the barangay level will be
acquired. Hot/coldspot classification of dengue incidence
rate will be achieved through analysis using Kulldorff ’s
scan statistic in SaTScan™ (version 9.1.1) (http://www.
satscan.org/) [40]. A discrete Poisson model will be used
to analyse the spatial distribution of dengue cases using
all 5 years of incidence data, with year as the analysis
time unit and population density as a covariate. Within
SaTScan™, an infinite number of cluster circles are gen-
erated with a minimum size diameter set to 300 m, the
approximate size of the future clusters. A maximum
value will initially be set to 1 km and then altered as a
function of the number and type (hot/cold) of clusters
detected. SaTScan™ identifies hot or cold spots that rep-
resent either more or less than the expected dengue
cases compared with the entire study area. SaTScan™
then calculates the relative risk of observed hot and
coldspots, and statistical significance of these spots is
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determined using a likelihood ratio test. Only spots with
no geographical overlap will be accepted. Areas that are
neither hotspots nor coldspots will be classified as inter-
mediate. Hot and cold spots will contain a variable num-
ber of puroks and it is possible, and indeed likely, that
hot and cold spots vary year to year. Therefore, puroks
will be classified by annual similarity, in other words
year 1 in hotspot, year 2 not, year 3 coldspot, and so on.
In this way puroks can be classified into a risk designa-
tion and matched for treatment and control site
selection.
Sero-conversion
Sero-conversion of individuals to DENV will be analysed
yearly using three saliva samples taken from each indi-
vidual during each year (six total samples per volunteer).
Because there are repeated measures from the same in-
dividual, sero-conversion is analysed using a generalised
linear mixed model (GLMM) with ‘individual’ as a ran-
dom factor. We will also include cluster ID, school, and
occurrence (yes/no) of any public health mosquito con-
trol intervention performed in the cluster, and when, as
random factors. Sero-conversion will be considered both
as 1) a four-fold titre rise in DENV IgG optical density
(OD) from baseline to post-treatment (year 1 or 2) sam-
ples, thus classifying individuals into yes/no (Y/N)
sero-conversion, and 2) the actual change in OD without
the restrictive definition of a four-fold increase. This
double analysis will enable assessment of change in IgG
OD beyond that using the classical threshold of an arbi-
trary four-fold increase. The Y/N IgG OD analysis will
use logistic regression and the latter OD measure
log-linear regression. Time (Post1 and Post2 for Y/N lo-
gistic regression; Pre-, Post1, and Post2 for log-linear re-
gression), treatment (intervention Y/N), age
(continuous), sex (male/female), vaccination status (0, 1,
2, 3 inoculation categories), and site (purok) risk (base-
line seropositive prevalence rate) will be the explanatory
variables. All analyses will be performed using Genstat
version 15 [41].
Adult mosquito spatial distributions (relative densities)
using GATs
Weekly adult mosquito catches will be analysed by fit-
ting a GLMM with the response variable as mosquitoes/
trap/week, time (week), and intervention (Y/N) as fixed
effects, and cluster ID and cluster risk designation as
random effects. In addition, we will include occurrence
of any public health mosquito control intervention per-
formed in the cluster by counting the numbers of days
during the 2 month inter-saliva sampling period when
mosquito numbers could have been affected by such a
control intervention (up to 14 days maximum
post-control) as a random factor. We will test for
over-dispersion in the response variable and, if it exists,
an over-dispersion parameter will be estimated and ap-
plied. Otherwise, a Poisson distribution will be assumed.
Two models will be constructed, one for each Aedes
dengue vector species.
Additionally, a second series of analyses involving the
distance of GATs from the nearest In2Care® trap will be
analysed using log-linear regression, fitting the actual
Euclidean distance in metres as a continuous variable.
Because the extent to which an area is built up can im-
pede mosquito flight (i.e. barriers), each cluster will be
categorised into an urban typology (categorical building
density) and this will be fitted as a factor in the analyses.
Data and trial monitoring
In the context of the Ecomore 2 project (www.ecomore.org/),
of which this trial is part, a Steering Committee com-
posed of five independent individuals has been cre-
ated. Their role is to: 1) monitor the progress of all
the projects towards their objectives, targeted results,
and identified milestones/indicators. Monitoring will
include annual presentations made by the Partners
and the coordination team to review status and pro-
gress of the various components and as well as field
visits, if relevant; 2) discuss and validate the pro-
posals, recommendations, and guidelines released by
the Project Coordinator, the Partners, or the Scientific
Advisors; 3) ensure that recommendations/requests is-
sued by the Steering Committee and validated by the
Partners through the acceptance of the Steering Com-
mittee minutes have effectively been translated into
action in the subsequent months; and 4) decide, if ne-
cessary, adjustments to the activities programme and
original schedules and provide corrective actions on
the methodology. All modifications must be clearly
stated and formally accepted by the Consortium
members (Project coordinator and partners in each
participating country).
Dissemination policy and access to data
Results will be communicated to trial participants
through general dissemination meetings and
language-adapted leaflets in Tagalog (the national lan-
guage of the Philippines). Scientific publishing will be in
open access, peer-reviewed journals and involve all sci-
entific collaborators, the authors of this manuscript, and
others as appropriate. The final results will be presented
following the CONSORT 2010 statement and the exten-
sion to cluster randomised trials [42]. This study proto-
col follows the recommendations outlined in SPIRIT
(Standard Protocol Items: Recommendations for Clinical
Trials) (Additional file 4) and the minimum trial regis-
tration information of WHO (Additional file 5). The trial
is also registered with International Standard Registered
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Clinical/Social Study Number (ISRCTN). After the pro-
ject has officially ended, access to the fully anonymised
trial dataset will be made available through the Dryad
Digital Repository and all protocols and samples of un-
filled consent/information forms and case report forms
will be freely available from the authors.
Archiving
The following documents will be archived for 15 years
following the completion of the study: signed research
protocol by all research partners (an original kept with
each of the partners and an original of all partner signa-
tures with the promoter of the research); consents/non--
opposition signed form (original only); observation
book/data collection medium (original with initiator of
the research and copied to the investigators and/or other
collaborators); and final report of the study and formal
publications.
Discussion
It is commonly accepted that an integrated approach to
vector control is required to be effective in reducing
transmission risk. The WHO Global Strategic Frame-
work for Integrated Vector Management (IVM) recom-
mends a range of interventions in combination to
increase impact [43]. Currently, the majority of countries
adhere, at least as published policy, to WHO recommen-
dations on mosquito control including source reduction
(environmental hygiene and community-based clean-up
campaigns), larvicidal treatment of water storage con-
tainers, and peridomestic space spraying of insecticides
around homes of recent dengue cases [44]. However,
there is currently no definitive evidence that these mea-
sures have any demonstrable effect on reducing dengue
transmission [11, 24, 25].
This efficacy trial of the first commercial product
using the AD approach will be highly informative as to
the general utility of AD in reducing not only vector
mosquito densities but, more importantly, actually redu-
cing the risk of dengue infection. The AD technique
may complement typical source reduction practices and
larviciding campaigns by more efficiently targeting the
most productive containers upon which the female mos-
quito fixes and contaminates the larval habitat, and im-
portantly those sites beyond access for human manual
treatment. AD is potentially a more effective interven-
tion than adult mosquito lethal traps because its impact
is amplified between the dissemination devices and the
larval habitats, in other words a small number of devices
can contaminate a much wider number of habitats [12,
16]. Despite some evidence that PPF disseminated by
AD can be effective [12, 15, 23], there remain several ob-
stacles to be overcome. Firstly, the AD devices need to
attract sufficient mosquitoes and thus depend not only
on the local abundance of mosquitoes but also on the at-
tractiveness of the AD device in the face of other com-
petitive sites. Secondly, studies in urban areas have
shown that topography is important for the movement
of mosquitoes (e.g. solid structure barriers impeding dis-
semination) [45]. This implies that AD devices may have
to be deployed at very high and operationally impractic-
able densities. Furthermore, the In2Care® recommenda-
tion in areas having high numbers of potential
alternative larval habitats is 1 device every 400 m2, the
equivalent to one trap per 20 m. This high trap density
is unlikely to be feasible or even welcome by a commu-
nity. Thus, there is need for the development of more
operationally useful and practical strategies for incorpor-
ation of AD approaches into larger, integrated mosquito
control programmes. Finally, as with all insecticides, the
risk of resistance developing against PPF is a real possi-
bility; therefore, resistance management strategies are re-
quired to mitigate this threat.
The evolution of resistance to PPF has been well docu-
mented for agricultural pests, most notably for the cot-
ton whitefly Bemisia tabaci where PPF resistance
became so high in some areas of Israel that it was dis-
continued [46]. Learning from this unfortunate outcome,
an insecticide resistance management (IRM) programme
was implemented in the US with recommendations for
early season, single application, threshold-based treat-
ments of PPF, coupled with a later season application of
broad-spectrum insecticides [47]. Metabolic resistance in
both housefly and whitefly to PPF was attributed to mu-
tations in enzyme activities of cytochrome P450
mono-oxygenases and glutathione S-transferases [48,
49], but resulting in a fitness cost that may have helped
retard the development of resistance under field condi-
tions when IRM is applied [46, 49]. Using an alternating
application of several insecticides with different physio-
logical modes of action has long been a strategy to com-
bat resistance of insects to chemical control agents. The
addition of the slower-acting entomopathogenic fungus
against adult mosquitoes may contribute to a reduction
in the rate of selection pressure for resistance against
PPF, in addition to its lethal and pre-lethal effects on the
mosquito. The fungus has been shown to counter the ef-
fect of insecticide resistance in anopheline mosquitoes
[50, 51]. The extent to which resistance can develop
against entomopathogenic fungi remains uncertain;
whilst it can be selected for, the associated fitness cost to
the insect suggests that it is less likely to arise in field
settings [52–54]. Indeed, the slow action of the fungus
potentially makes it ‘evolution-proof ’, as its lethal effect
occurs primarily in older mosquitoes that have had the
opportunity to breed [55]. The temporal requirement of
evolution-proof insecticides is to allow mosquitoes time
to develop and oviposit viable eggs but prevent them
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from transmitting pathogens. Insofar as DENV takes ap-
proximately 10 days incubation time from imbibing an
infective bloodmeal to being transmitted to a susceptible
host, this enables implementation of a slower-acting in-
secticidal agent whilst reducing onward DENV transmis-
sion. This balance is, however, fine and predicated on
the circumstances. In conclusion, a resistance manage-
ment programme should be envisaged if AD mosquito
traps prove effective.
Whilst the epidemiological efficacy of the new tool is
fundamental, community involvement and optimising
strategies for the public health sector can greatly en-
hance the utility and success of an intervention. In
addition to combining different mosquito control tools,
the WHO IVM strategy emphasises the necessity to con-
sider the societal impact, public opinion, and awareness
in the viability and acceptability of any intervention
strategy [56]. The IVM approach also emphasises the
importance of strengthening the public and private sec-
tors involved in decision-making and implementation of
mosquito control strategies. Carrying out the trial in
close collaboration with the local public health sector
and included communities is an important step in enab-
ling local support and continuity for vector control.
Surveillance is also an essential component of dengue
control because it provides spatial-temporal information
on the number and distribution of disease cases and the
relative intensity of transmission. Reliable and timely
surveillance data allow programmes to target interven-
tions appropriately and to respond to outbreaks quickly.
However, integrated epidemiological, entomological, and
intervention data are often unavailable and are
time-consuming to collate and analyse. This poses a sig-
nificant challenge to dengue control because the most
effective control programmes will likely utilise several
complementary interventions. The public health sector
is a domain under continuous change and development,
and novel methods for improving capacity are increas-
ingly available. Emerging information technologies are
improving our capacity to predict, prevent, and control
vector-borne and other infectious diseases [57].
Data-rich epidemiological studies and robust surveil-
lance programmes will benefit enormously from such
technological advances that will enable rapid collection
and analysis of standardised disease and vector data.
Continuous surveillance, monitoring, and evaluation
using real-time data enables vector-borne disease control
programmes to rapidly identify disease occurrence,
monitor specific intervention effectiveness, and plan ap-
propriate interventions.
In conclusion, there is a suite of technological tools
for the development of more up-to-date approaches to
vector mosquito control to reduce viral pathogens trans-
mitted by Aedes aegypti and similar species. However,
new tools require validation under field conditions be-
fore optimisation for wide-scale and routine application.
Well-executed evaluations for assisting local public
health sectors to achieve technologically advanced man-
agement of their mosquito control strategies are a sine
qua non for reducing the burden of mosquito-borne
disease.
Study limitations
The major concern of the study will be the dependency
on there being sufficient dengue activity during at least
one of the study years and that the cluster design is suf-
ficient to account for the recognised spatio-temporal
heterogeneity in dengue [58, 59]. To maximise power
and somewhat alleviate this concern, sero-conversion ra-
ther than dengue case incidence will be used as the
measure of epidemiological outcome, capturing the
sub-clinical infections that form the majority of dengue
infections [60, 61]. Continued compliance of participants
during the 2 years may pose a problem as will commu-
nity acceptance of the In2Care® traps and GAT devices.
Considerable effort will be given to continuous dialogue
with the community to maintain adherence throughout
the study.
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